MedTrace Logo

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

NCT06761898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-09-04

No results posted yet for this study

Summary

Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BGB-43395

Administered orally as solid dispersion tablet or salt tablet

DRUG

BGB-43395

Administered orally as solid dispersion tablet or salt tablet

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-14
Primary Completion
2025-05-20
Completion
2025-05-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06761898 on ClinicalTrials.gov